{"id":70591,"date":"2026-07-24T20:44:41","date_gmt":"2026-07-24T12:44:41","guid":{"rendered":"https:\/\/flcube.com\/?p=70591"},"modified":"2026-07-24T20:44:42","modified_gmt":"2026-07-24T12:44:42","slug":"genmab-abbvie-epcoritamab-phase-3-trial-misses-primary-os-endpoint-in-u-s-for-relapsed-refractory-dlbcl","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70591","title":{"rendered":"Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\/Refractory DLBCL"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Genmab A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/GMAB:NASDAQ\">NASDAQ: GMAB<\/a>) and <strong>AbbVie Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) announced on <strong>July 23, 2026<\/strong> that the <strong>Phase 3 EPCORE DLBCL-1 study<\/strong> evaluating <strong>epcoritamab monotherapy<\/strong> versus investigator&#8217;s choice chemoimmunotherapy failed to meet its primary endpoint in the United States. The trial, which compared the T-cell engaging bispecific antibody against standard regimens in adults with <strong>relapsed or refractory diffuse large B-cell lymphoma (DLBCL)<\/strong> ineligible for autologous stem cell transplantation, did not demonstrate statistically significant improvement in <strong>overall survival (OS)<\/strong>\u2014the sole primary endpoint for the U.S. regulatory region.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-overview\" class=\"wp-block-heading\">Clinical Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Name<\/strong><\/td><td>EPCORE DLBCL-1<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>Phase 3, global, open-label, multi-center, randomized<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults with R\/R DLBCL ineligible for autologous stem cell transplantation<\/td><\/tr><tr><td><strong>Intervention<\/strong><\/td><td>Epcoritamab monotherapy (CD3xCD20 bispecific antibody)<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Investigator&#8217;s choice: R-GemOx (rituximab + gemcitabine + oxaliplatin) or BR (bendamustine + rituximab)<\/td><\/tr><tr><td><strong>U.S. Primary Endpoint<\/strong><\/td><td>Overall Survival (OS)<\/td><\/tr><tr><td><strong>Trial Outcome (U.S.)<\/strong><\/td><td>Did not meet primary endpoint \u2013 no statistically significant OS improvement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-current-status\" class=\"wp-block-heading\">Drug Profile &amp; Current Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Epcoritamab:<\/strong> T-cell engaging <strong>bispecific antibody<\/strong> targeting <strong>CD3<\/strong> (T-cell receptor) and <strong>CD20<\/strong> (B-cell marker), designed to redirect T-cells to eliminate malignant B-cells<\/li>\n\n\n\n<li><strong>Current Approval:<\/strong> Granted under <strong>FDA&#8217;s accelerated approval pathway<\/strong> for adult patients with R\/R DLBCL, not otherwise specified (NOS), including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma, after two or more lines of systemic therapy<\/li>\n\n\n\n<li><strong>Mechanism Advantage:<\/strong> Subcutaneous administration offers convenience over intravenous therapies, with potential for outpatient treatment<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> Part of Genmab and AbbVie&#8217;s broader collaboration to develop epcoritamab across multiple B-cell malignancies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regional-endpoint-differences\" class=\"wp-block-heading\">Regional Endpoint Differences<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. Regulatory Framework:<\/strong> FDA required <strong>overall survival<\/strong> as the confirmatory endpoint for converting accelerated approval to full approval<\/li>\n\n\n\n<li><strong>Other Regions:<\/strong> Trial included <strong>prespecified primary endpoints that differ by region<\/strong>, potentially including progression-free survival (PFS) or other surrogate endpoints acceptable to non-U.S. regulatory authorities<\/li>\n\n\n\n<li><strong>Statistical Implications:<\/strong> Failure to demonstrate OS benefit in the U.S. population may impact the drug&#8217;s commercial trajectory in the world&#8217;s largest pharmaceutical market<\/li>\n\n\n\n<li><strong>Accelerated Approval Risk:<\/strong> Results raise questions about potential <strong>accelerated approval withdrawal<\/strong> if confirmatory evidence fails to verify clinical benefit<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Exposure:<\/strong> DLBCL represents one of the most common forms of non-Hodgkin lymphoma, with approximately <strong>25,000 new cases annually in the U.S.<\/strong> alone<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Epcoritamab competes with other CD20-targeting therapies, CAR-T products (Yescarta, Breyanzi), and emerging bispecific antibodies (mosunetuzumab, glofitamab)<\/li>\n\n\n\n<li><strong>Partnership Dynamics:<\/strong> Genmab retains U.S. commercial rights while AbbVie holds ex-U.S. rights, creating asymmetric financial impact from the trial outcome<\/li>\n\n\n\n<li><strong>Investment Reaction:<\/strong> Genmab shares are expected to face pressure following the announcement, while AbbVie&#8217;s diversified portfolio may provide insulation from single-product setbacks<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-path-considerations\" class=\"wp-block-heading\">Forward Path Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Engagement:<\/strong> Companies will likely engage with FDA to discuss potential pathways forward, including analysis of secondary endpoints or subgroup populations<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Success in non-U.S. regions could still support international commercial expansion, depending on regional endpoint results<\/li>\n\n\n\n<li><strong>Pipeline Diversification:<\/strong> Both companies maintain robust oncology pipelines, with epcoritamab being evaluated in earlier lines of therapy and combination regimens<\/li>\n\n\n\n<li><strong>Clinical Practice Impact:<\/strong> Despite OS results, clinicians may continue using epcoritamab based on response rates, safety profile, and patient convenience factors<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial outcomes, regulatory pathways, and commercial expectations. Actual results may differ due to regulatory decisions, competitive dynamics, and evolving clinical practice patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Genmab A\/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[234,17,368,851,853],"class_list":["post-70591","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abbvie","tag-clinical-trial-results","tag-genmab","tag-nasdaq-gmab","tag-nyse-abbv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\/Refractory DLBCL - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Genmab A\/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that the Phase 3 EPCORE DLBCL-1 study evaluating epcoritamab monotherapy versus investigator&#039;s choice chemoimmunotherapy failed to meet its primary endpoint in the United States. The trial, which compared the T-cell engaging bispecific antibody against standard regimens in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplantation, did not demonstrate statistically significant improvement in overall survival (OS)\u2014the sole primary endpoint for the U.S. regulatory region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70591\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\/Refractory DLBCL\" \/>\n<meta property=\"og:description\" content=\"Genmab A\/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that the Phase 3 EPCORE DLBCL-1 study evaluating epcoritamab monotherapy versus investigator&#039;s choice chemoimmunotherapy failed to meet its primary endpoint in the United States. The trial, which compared the T-cell engaging bispecific antibody against standard regimens in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplantation, did not demonstrate statistically significant improvement in overall survival (OS)\u2014the sole primary endpoint for the U.S. regulatory region.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70591\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-24T12:44:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-24T12:44:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70591#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70591\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\\\/Refractory DLBCL\",\"datePublished\":\"2026-07-24T12:44:41+00:00\",\"dateModified\":\"2026-07-24T12:44:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70591\"},\"wordCount\":568,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"Clinical trial results\",\"Genmab\",\"NASDAQ: GMAB\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70591#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70591\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70591\",\"name\":\"Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\\\/Refractory DLBCL - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-24T12:44:41+00:00\",\"dateModified\":\"2026-07-24T12:44:42+00:00\",\"description\":\"Genmab A\\\/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that the Phase 3 EPCORE DLBCL-1 study evaluating epcoritamab monotherapy versus investigator's choice chemoimmunotherapy failed to meet its primary endpoint in the United States. The trial, which compared the T-cell engaging bispecific antibody against standard regimens in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplantation, did not demonstrate statistically significant improvement in overall survival (OS)\u2014the sole primary endpoint for the U.S. regulatory region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70591#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70591\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70591#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\\\/Refractory DLBCL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\/Refractory DLBCL - Insight, China&#039;s Pharmaceutical Industry","description":"Genmab A\/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that the Phase 3 EPCORE DLBCL-1 study evaluating epcoritamab monotherapy versus investigator's choice chemoimmunotherapy failed to meet its primary endpoint in the United States. The trial, which compared the T-cell engaging bispecific antibody against standard regimens in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplantation, did not demonstrate statistically significant improvement in overall survival (OS)\u2014the sole primary endpoint for the U.S. regulatory region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70591","og_locale":"en_US","og_type":"article","og_title":"Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\/Refractory DLBCL","og_description":"Genmab A\/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that the Phase 3 EPCORE DLBCL-1 study evaluating epcoritamab monotherapy versus investigator's choice chemoimmunotherapy failed to meet its primary endpoint in the United States. The trial, which compared the T-cell engaging bispecific antibody against standard regimens in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplantation, did not demonstrate statistically significant improvement in overall survival (OS)\u2014the sole primary endpoint for the U.S. regulatory region.","og_url":"https:\/\/flcube.com\/?p=70591","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-24T12:44:41+00:00","article_modified_time":"2026-07-24T12:44:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70591#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70591"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\/Refractory DLBCL","datePublished":"2026-07-24T12:44:41+00:00","dateModified":"2026-07-24T12:44:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70591"},"wordCount":568,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","Clinical trial results","Genmab","NASDAQ: GMAB","NYSE: ABBV"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70591#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70591","url":"https:\/\/flcube.com\/?p=70591","name":"Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\/Refractory DLBCL - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-24T12:44:41+00:00","dateModified":"2026-07-24T12:44:42+00:00","description":"Genmab A\/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that the Phase 3 EPCORE DLBCL-1 study evaluating epcoritamab monotherapy versus investigator's choice chemoimmunotherapy failed to meet its primary endpoint in the United States. The trial, which compared the T-cell engaging bispecific antibody against standard regimens in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplantation, did not demonstrate statistically significant improvement in overall survival (OS)\u2014the sole primary endpoint for the U.S. regulatory region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70591#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70591"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70591#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed\/Refractory DLBCL"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70591"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70591\/revisions"}],"predecessor-version":[{"id":70592,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70591\/revisions\/70592"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}